13.03
Precedente Chiudi:
$13.52
Aprire:
$13.22
Volume 24 ore:
1.70M
Relative Volume:
0.45
Capitalizzazione di mercato:
$1.39B
Reddito:
$64.52M
Utile/perdita netta:
$-95.55M
Rapporto P/E:
-12.81
EPS:
-1.0169
Flusso di cassa netto:
$-84.65M
1 W Prestazione:
+6.11%
1M Prestazione:
-9.14%
6M Prestazione:
+61.76%
1 anno Prestazione:
+195.80%
Personalis Inc Stock (PSNL) Company Profile
Nome
Personalis Inc
Settore
Industria
Telefono
650-752-1300
Indirizzo
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
PSNL
Personalis Inc
|
13.03 | 1.28B | 64.52M | -95.55M | -84.65M | -1.0169 |
|
TMO
Thermo Fisher Scientific Inc
|
580.02 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
199.98 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
590.00 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
141.34 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
|
WAT
Waters Corp
|
399.70 | 36.45B | 3.77B | 449.25M | 240.68M | 7.8556 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Iniziato | Guggenheim | Buy |
| 2025-03-17 | Iniziato | Craig Hallum | Buy |
| 2023-02-06 | Aggiornamento | Needham | Hold → Buy |
| 2022-01-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Downgrade | Needham | Buy → Hold |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-20 | Reiterato | Needham | Buy |
| 2021-05-06 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-12 | Reiterato | Needham | Buy |
| 2020-11-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2019-09-26 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Iniziato | BofA/Merrill | Neutral |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Morgan Stanley | Overweight |
| 2019-07-15 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Personalis Inc Borsa (PSNL) Ultime notizie
PSNL|Personalis Inc|Price:11.989|Chg%:+0.209 - TradingKey
Personalis Inc (PSNL) Valuation: PE, PB & Fair Value Analysis - TradingKey
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Tempus AI Stock (TEM) Opinions on Personalis Acquisition and Analyst Upgrades - Quiver Quantitative
Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring - Oncodaily
Personalis Inc (PSNL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tempus to buy cancer test maker Personalis for $1.5 billion - AOL.ca
Personalis Inc (PSNL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Personalis Inc (PSNL) Income Statement - TradingKey
Tempus AI buys Personalis for $1.5B; UCSF Health, Kleiner Perkins and Doerr Capital launch health AI accelerator; Candid Health raises $120M - VatorNews
Tempus to acquire Personalis in $1.5 billion deal to expand MRD capabilities - DOTmed
Personalis Inc (PSNL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kalpesh Patel: The Fifth MRD Buyout in Less Than a Year - Oncodaily
Why Is PSNL Stock Up 5% After-Hours? - Stocktwits
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Tempus makes $1.5B bet to corner cancer-test market - thestreet.com
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring - Sahm
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasd - Supply Chain Digital
Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership - finance.biggo.com
Personalis (PSNL) Proxy filing Summary - Quartr
Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In - Yahoo Finance
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc.PSNL - The AI Journal
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks - Sahm
Tempus to acquire Personalis, Inc. (PSNL) in cash and stock merger - Stock Titan
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $16.25 - Moomoo
Why Is Tempus AI Stock Volatile Tuesday?Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM) - Benzinga
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL) - Morningstar
Tempus AI buys Personalis for $1.5 billion - grafa.com
Personalis: Tempus Bought The Best Part Of The Story (NASDAQ:PSNL) - Seeking Alpha
Tempus AI Buys Personalis for $1.5B to Boost Cancer Monitoring - Medical Device and Diagnostic industry
Tempus AI to Acquire Personalis for $1.5 Billion to Expand Precision Oncology Platform - HLTH
Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal - qz.com
Tempus AI Acquires Personalis: Why Both Stocks Are A Buy Now (NASDAQ:TEM) - Seeking Alpha
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion - Yahoo Finance
Tempus to acquire Personalis - Medical Buyer
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal - Yahoo Finance
Tempus AI snaps up genomics partner Personalis for $1.5 billion - The Pharma Letter
Tempus AI (TEM) to Acquire Personalis in Strategic Move - GuruFocus
Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring - Yahoo Finance
AI healthcare company acquires US biotech firm for USD 1.7bn - medwatch.com
Personalis (PSNL) Registration Filing Summary - Quartr
TEM, PSNL stocks are falling — why Morgan Stanley still likes Tempus AI’s Personalis deal - MSN
Personalis, Inc. (PSNL) Tempus AI, Inc.M&A CallSlideshow (NASDAQ:PSNL) 2026-07-20 - Seeking Alpha
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
Daily Brief United States: Meta, Gold, Braemar Hotels & Resorts , AIOS, Alarm.Com Holdings, Personalis Inc, Arcbest Corp, New Horizon Aircraft, Jersey Mike's Subs, Crude Oil and more - Smartkarma
Personalis Price Target Announced at $16.25/Share by Lake Street - Moomoo
AI-Driven Tempus Acquires Cancer Diagnostics Firm Personalis for $1.7B in Stock - Briefs Finance
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink -- Barrons.com - Moomoo
Tempus AI Acquires Personalis For $1.5bn To Expand MRD Cancer Testing - insights.citeline.com
Tempus AI (TEM) plans stock-plus-cash merger with Personalis (PSNL) - Stock Titan
Personalis (NASDAQ: PSNL) agrees to stock-for-stock merger with Tempus AI - Stock Titan
Personalis Inc Azioni (PSNL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Personalis Inc Azioni (PSNL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Chen Richard | President and CMO |
Jul 15 '26 |
Sale |
15.15 |
100,000 |
1,515,000 |
173,880 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):